96. Crohn disease Clinical trials / Disease details

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-005702-37-NL (EUCTR)	08/04/2015	12/02/2015	Early infliximab use in kids with Crohn's disease (TISKids)	Top-Down Infliximab Study in Kids with Crohn's disease (TISKids) - Top-down Infliximab in Kids with Crohn's disease (TISKids)	Crohn's disease;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Inflectra INN or Proposed INN: INFLIXIMAB Other descriptive name: Inflectra	Erasmus Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 4	Netherlands
2	NCT02517684 (ClinicalTrials.gov)	April 2015	1/7/2015	Top-down Infliximab Study in Kids With Crohn's Disease	Top-down Infliximab Study in Kids With Crohn's Disease	Crohn's Disease	Drug: Infliximab;Drug: Prednisolone;Other: Exclusive enteral nutrition;Drug: Azathioprine	Erasmus Medical Center	ZonMw: The Netherlands Organisation for Health Research and Development;Hospira, now a wholly owned subsidiary of Pfizer	Active, not recruiting	3 Years	17 Years	All	100	Phase 4	Belgium;Finland;Netherlands;Denmark;Italy;Poland
3	EUCTR2012-000645-13-BE (EUCTR)	09/09/2013	16/07/2013	Infliximab as firsdt treatment instead of second line treatment in Crohns disease	Infliximab Top-down Study in Kids with Crohn’s disease - ITSKIDS	Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remicade	ErasmusMC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	90		Belgium;Netherlands
4	NCT01880307 (ClinicalTrials.gov)	January 2013	7/6/2013	Infliximab Top-down in Pediatric Crohn	Infliximab Top-down Study in Kids With Crohn's Disease	Crohn's Disease	Drug: Azathioprine;Drug: Infliximab;Drug: Prednisolon	Erasmus Medical Center	University of Roma La Sapienza;University Hospital, Brussels	Terminated	3 Years	17 Years	Both	13	Phase 4	Italy;Netherlands
5	NCT01752790 (ClinicalTrials.gov)	December 2012	12/12/2012	Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease	Efficacy and Safety of Infliximab as First-line Therapy in Pediatric Crohn's Disease: a Randomized, Controlled, Open-label Trial	Pediatric Crohn's Disease	Drug: Top-down;Drug: Step-up	University of Roma La Sapienza	NULL	Withdrawn	6 Years	18 Years	Both	0	Phase 4	Italy
6	EUCTR2012-000645-13-NL (EUCTR)	17/10/2012	12/07/2012	Infliximab as first treatment instead of second line treatment in Crohns disease	Infliximab Top-down Study in Kids with Crohn’s disease - ITSKIDS	Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remicade	ErasmusMC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	90		Belgium;Netherlands;Italy